Istanbul Medical Journal is a prominent open-access journal published by GALENOS PUBL HOUSE, dedicated to disseminating high-quality research in the field of medicine since its inception in 1994. The journal, identifiable by its ISSN 2619-9793 and E-ISSN 2148-094X, serves as a critical platform for healthcare professionals, researchers, and students who aim to share innovative studies and advancements within diverse medical domains. Its commitment to open access ensures that crucial findings and discussions are readily available to a global audience, fostering collaboration and knowledge exchange among the scientific community. Located in Istanbul, Türkiye, the journal not only contributes to the medical literature landscape but also emphasizes the importance of accessibility in research, aligning with current academic trends that prioritize the transmission of knowledge across barriers. As a resource for those involved in healthcare and medical research, the Istanbul Medical Journal plays a vital role in shaping future developments in medicine.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

The New England Journal of Medicine (NEJM), published by the Massachusetts Medical Society, stands as a beacon of excellence in the field of medicine. With an impressive impact factor and a prestigious rank of #2 out of 636 in General Medicine, NEJM is recognized in the Q1 category for its significant contributions to medical research and clinical practice since its inception in 1945. The journal is renowned for publishing groundbreaking studies, reviews, and commentaries that influence clinical guidelines and healthcare policies worldwide. While the journal is not open access, it provides pivotal resources that are essential for researchers, healthcare professionals, and students looking to stay abreast of the latest developments in medicine. With a commitment to advancing medical knowledge, NEJM plays a crucial role in bridging the gap between laboratory research and clinical application.

European Journal of Integrative Medicine is a prestigious academic publication under the esteemed Elsevier Science Inc., dedicated to advancing knowledge in the field of Complementary and Alternative Medicine. With an ISSN of 1876-3820 and an E-ISSN of 1876-3839, this journal serves as a pivotal platform for researchers, professionals, and students alike, aiming to explore the integration of holistic practices with conventional medicine. With a Q2 ranking in the 2023 Scopus category for Complementary and Alternative Medicine, and a commendable percentile of 75th, the journal underscores its significance in fostering scholarly discourse and supporting innovative research from 2009 to 2024. The European Journal of Integrative Medicine does not currently offer open access options, encouraging subscription-based access that promotes the quality of published research. This journal is subsequently an essential resource for anyone seeking to deepen their understanding of integrative health approaches and their clinical applications in contemporary medicine.

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

Journal of Personalized Medicine is a pioneering open-access journal published by MDPI, renowned for its commitment to advancing research in the dynamic field of personalized healthcare. Since its inception in 2011, this journal has served as a critical platform for scholars, practitioners, and students interested in the integration of individualized therapies and diagnostic techniques that aim to tailor medical treatments to the unique characteristics of each patient. With an impressive Q2 ranking in the field of medicine, as recognized by Scopus, and currently holding a percentile rank of 65th, it stands out among its peers with a focus on innovative approaches that challenge traditional paradigms. Researchers can benefit from its open-access model, allowing for broader dissemination of findings that can significantly impact clinical practices and research directions globally. Set against the picturesque backdrop of Basel, Switzerland, the journal is positioned at the forefront of medical innovation, producing high-quality, peer-reviewed articles that span the latest advancements and applications in personalized medicine.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

Global Journal of Medical Pharmaceutical and Biomedical Update, published by SCIENTIFIC SCHOLAR LLC, is a premier platform dedicated to advancing knowledge in the fields of medicine, pharmaceuticals, and biomedical sciences. With an E-ISSN of 2765-8910, this journal aims to foster innovative research and insightful discussions by providing open access to high-quality peer-reviewed articles. It serves as an invaluable resource for researchers, professionals, and students alike, ensuring that the latest advancements, methodologies, and findings are accessible to a diverse audience. Located at 50, Woodgreen Dr, Pittsford, NY 14534, the journal prioritizes the dissemination of critical information that addresses the evolving challenges faced in healthcare and biomedical research, ultimately contributing to the betterment of global health outcomes.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, published by SAGE Publications Ltd, serves as a vital platform in the fields of biochemistry and medicine, showcasing significant research contributions since its inception in 1972. With an Open Access policy implemented in 2012, this journal promotes unrestricted dissemination of knowledge, catering to a global audience and ensuring that critical findings are accessible to researchers, healthcare professionals, and students alike. With an impressive scope spanning diverse biomedical disciplines, the journal ranks in the Q3 quartile for both biochemistry and medicine, affirming its relevance and impact within these evolving fields. Hailing from the United Kingdom, the journal is dedicated to fostering a rich academic dialogue that bridges laboratory discoveries and clinical applications, making it an essential resource for those engaged in international medical research. Its ongoing commitment to excellence is reflected in its convergence until 2024, inviting high-quality submissions that contribute to advancements in medical science.